---
schema_version: "secwatch.filing_event.v1"
accession: "0001935979-24-000047"
form_type: "8-K"
ticker: "BHVN"
cik: "0001935979"
company_name: "Biohaven Ltd."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T07:16:03.489382+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Biohaven Q1 net loss $179.5M ($2.20/shr) vs $70.5M loss a year ago; cash $287.6M plus $247.8M from April offering

## Summary
- Net loss $179.5M ($2.20/shr); non-GAAP adjusted net loss $144.6M ($1.77/shr); both more than doubled vs Q1 2023.
- R&D expense $156.0M, up 146% YoY, driven by advancing trials and $16.6M in shares for Pyramid Biosciences acquisition.
- Cash, equivalents and marketable securities $287.6M at March 31; additional $247.8M from April 2024 public offering of 6.45M shares at $41.
- FDA granted rare pediatric disease designation for taldefgrobep alfa in SMA; Phase 3 data expected 2H 2024.
- Phase 2/3 programs initiated with Kv7 activator BHV-7000 in epilepsy, MDD, and bipolar; BHV-1300 MoDE shows IgG reduction.

## SEC filing metadata
- accession: 0001935979-24-000047
- form_type: 8-K
- ticker: BHVN
- cik: 0001935979
- company_name: Biohaven Ltd.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1935979/000193597924000047/0001935979-24-000047-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1935979/000193597924000047/bhvn-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001935979-24-000047
- JSON: https://secwatch.observer/filing/0001935979-24-000047.json
- Plain text: https://secwatch.observer/filing/0001935979-24-000047.txt

## Key facts
- Earnings Releases
  Biohaven Ltd. reported financial results for first quarter ended March 31, 2024.
  - Period: first quarter ended March 31, 2024
  - Result: reported results
  source text: Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today reported financial results for the first quarter ended March 31, 2024, and provided a review of recent accomplishments and anticipated upcoming developments.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1935979/000193597924000047/0001935979-24-000047-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.